Methods for rapid detection and identification of bioagents in epidemiological and forensic investigations
View Patent ↗The present invention provides methods for rapid forensic investigations by identification of bioagents associated with biowarfare and acts of terrorism or crime. The methods are also useful for epidemiological investigations by genotyping of bioagents.
1. A method of determining the genotype of a bioagent comprising the steps of:
selecting at least one pair of oligonucleotide primers, wherein one member of said pair of primers hybridizes to a first conserved region of nucleic acid encoding a ribosomal RNA and the other member of said pair of primers hybridizes to a second conserved region of nucleic acid encoding said ribosomal RNA wherein said first and second conserved regions flank a variable nucleic acid region that when amplified creates a unique base composition signature among at least eight bioagents;
amplifying nucleic acid from at least one said bioagent with said pair of oligonucleotide primers to produce an amplification product;
determining the molecular mass of said amplification product by mass spectrometry;
calculating the base composition of said amplification product from said molecular mass;
comparing said base composition of at least one said bioagent to nineteen or more calculated or measured base compositions of amplification products of known bioagents produced by using said at least one pair of oligonucleotide primers, thereby identifying said unknown bioagent at the species level; and
identifying a sub-species characteristic of said bioagent, thereby determining the genotype of said bioagent.
2. The method of claim 1 wherein said sub-species characteristic comprises at least one single nucleotide polymorphism.
3. The method of claim 1 wherein the molecular masses of said amplification products are determined by ESI-TOF mass spectrometry.
4. The method of claim 1 wherein said bioagent is a bacterium, mold, fungus or parasite.
5. A method of determining the genotype of a bioagent comprising the steps of:
selecting at least one pair of oligonucleotide primers, wherein one member of said pair of primers hybridizes to a first conserved region of a nucleic acid encoding a protein that participates in translation, replication, recombination, repair, transcription, nucleotide metabolism, amino acid metabolism, lipid metabolism, uptake, secretion, antibiotic resistance, virulence, or pathogenicity, and the other member of said pair of primers hybridizes to a second conserved region of said nucleic acid encoding a protein that participates in translation, replication, recombination, repair, transcription, nucleotide metabolism, amino acid metabolism, lipid metabolism, uptake, secretion, antibiotic resistance, virulence, or pathogenicity, wherein said first and second conserved regions flank a variable nucleic acid region that when amplified creates unique base composition signatures among at least eight bioagents;
amplifying nucleic acid from at least one said bioagent with said pair of oligonucleotide primers to produce an amplification product;
determining the molecular mass of said amplification product by mass spectrometry;
calculating the base composition of said amplification product from said molecular mass;
comparing said base composition of at least one said bioagent to nineteen or more calculated or measured base compositions of amplification products of known bioagents produced by using said at least one pair of oligonucleotide primers, thereby identifying said unknown bioagent at the species level; and
identifying a sub-species characteristic of said bioagent, thereby determining the genotype of said bioagent.
6. The method of claim 5 wherein said sub-species characteristic comprises at least one single nucleotide polymorphism.
7. The method of claim 5 wherein said sub-species characteristic comprises a pathogenicity factor.
8. The method of claim 7 wherein said pathogenicity factor is a pathogenicity island, a virulence marker, or a toxin gene.
9. The method of claim 8 wherein said toxin gene has been inserted by genetic engineering.
10. The method of claim 5 wherein said molecular masses of said amplification products are determined by ESI-TOF mass spectrometry.
11. The method of claim 5 wherein said bioagent is a bacterium, virus, mold, fungus or parasite.